On April 30, 2026, The Lancet published the largest randomized trial to date of semaglutide for alcohol use disorder. In 108 adults with comorbid AUD and obesity, 26 weeks of once-weekly 2.4 mg semaglutide cut heavy drinking days by 41.1 percentage points — 13.7 points more than placebo (p=0.0015). Number needed to treat: 4.3. That's better than every FDA-approved AUD medication on the market.
Research-context information only. Peptides discussed below are research compounds. Protocols, doses, and reactions reported come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
The Trial: Klausen et al., Lancet 2026
The phase 2b trial ran at Copenhagen University Hospital from June 2023 to February 2025, with results published online April 30, 2026 (DOI: 10.1016/S0140-6736(26)00305-3). First author Mette Kruse Klausen, M.D.; corresponding author Anders Fink-Jensen, D.M.Sc.
Design. Randomized, double-blinded, placebo-controlled, single-centre, 1:1 allocation. Treatment-seeking adults with moderate to severe alcohol use disorder (DSM-5 criteria) and BMI ≥30 received either once-weekly subcutaneous semaglutide titrated to 2.4 mg or saline placebo, both for 26 weeks. All participants received standard cognitive behavioral therapy on top of the injection (10 sessions focused on motivation, craving, and relapse prevention).
Sample. 108 enrolled (53 women, 55 men), 54 per arm, all included in analysis. Mean baseline weight elevated; mean baseline heavy drinking days substantial.
Primary endpoint. Reduction in heavy drinking days (defined as days with ≥4 standard drinks for women, ≥5 for men) over the trial period.
Result. Semaglutide arm: heavy drinking days fell 41.1 percentage points from baseline (95% CI –48.7 to –33.5). Placebo arm: 26.4 percentage points (95% CI –34.1 to –18.6). Estimated treatment difference: 13.7 percentage points (95% CI –22.0 to –5.4; p=0.0015). Translation: at 26 weeks, semaglutide patients were having heavy drinking days roughly 14% less of the time than placebo patients — on top of a placebo-plus-CBT effect that itself was sizeable.
Secondary signals. Decreases in body weight, blood pressure, and blood-alcohol biomarkers (PEth, gamma-GT) were more pronounced in the semaglutide arm. The biomarker concordance is the part that should make readers take this seriously — self-reported drinking is famously unreliable, but PEth (phosphatidylethanol) is a 2-4 week direct alcohol marker that's hard to fake. It moved with the self-report.
Number needed to treat: 4.3. Compare to FDA-approved AUD medications: naltrexone NNT ≈ 12, acamprosate NNT ≈ 12, disulfiram NNT highly variable. If this effect size holds in phase 3, semaglutide would become the most effective AUD pharmacotherapy ever tested in a controlled trial.
Adverse events. Gastrointestinal symptoms (nausea, constipation, decreased appetite) were more common on semaglutide but transient and mild. Discontinuation rates were not meaningfully different between arms in the published topline.
What This Means for You
If you're searching for semaglutide because you're trying to drink less, here's the practical read:
The dose that worked is 2.4 mg weekly — Wegovy/weight-loss territory. Not the lower diabetes-titrated 1.0–2.0 mg range. The Hendershot et al. JAMA Psychiatry trial in 2025 (PMID 39937469) tested low-dose semaglutide (0.5 mg) over 9 weeks and showed reductions in some lab measures of alcohol consumption but smaller real-world effects. The Lancet 2026 trial doubled down on the higher dose and longer duration, and the effect size grew substantially. Dose and duration matter.
CBT was part of the protocol. Both arms received cognitive behavioral therapy. Semaglutide on its own — without behavioral support — has not been tested at this scale for AUD. The 41% reduction is "drug + therapy," not "drug alone." Buyers expecting magic-bullet results from injection alone are extrapolating beyond the data.
This is phase 2b, not phase 3. Single-centre, 108 patients, 26 weeks. The signal is real and biologically supported, but a larger multi-site phase 3 would be the only way to know if the effect generalizes. Novo Nordisk has not publicly committed to running one for an AUD label.
For sourcing semaglutide today:
Ascension Peptides
9.5/1050% OFF · code THEPEPTIDECATALOGLowest effective pricing in the market after an exclusive 50% off through our link. Independent COA testing across the catalog.
Ion Peptide
9.2/1015% OFF · code thepeptidecatalogStrong blend lineup and competitive singles pricing. Pre-mixed combinations simplify reconstitution and dosing.
EZ Peptides
9.6/1010% OFF · code thepeptidecatalogBroadest verified catalog with QR-linked COAs on every product. Fast domestic shipping and a 30-day guarantee.
Glacier Aminos
9.3/1010% OFF · code thepeptidecatalogResearch peptide vendor with COA documentation and an exclusive 10% off discount.
Nura Peptide
9.2/1025% OFF · code thepeptidecatalogNiche-format vendor — oral capsule peptides, pre-mixed nasal solutions, and a rare Reta + Cagrilintide combo blend, all 25% off with code thepeptidecatalog.
Mile High Compounds
8.5/1010% OFF · code thepeptidecatalogPartner vendor with verified inventory and COA documentation.
Swiss Chems
9.2/1010% OFF · code THEPEPTIDECATALOGBroad catalog with international shipping — useful for researchers outside the US.
The above table is live — pulled from our vendor database, refreshed when admin toggles a recommendation. Click into a vendor row for current per-vial pricing and stock status. For mainstream research-grade semaglutide vials, EZ Peptides and Ascension Peptides are the cleanest options as of this writing — both have third-party COAs and ship from US warehouses.
For the prescription compounded route, see our semaglutide buying guide which compares telehealth providers, pharmacy options, and cost ranges. If you have AUD specifically, the prescription route is the more honest path — your doctor can write off-label, monitor liver enzymes, and adjust dose based on response.
